Aisen P, Bateman RJ, Crowther D, Cummings J, et al. The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence. Alzheimers Dement 2024 Nov 13. doi: 10.1002/alz.14342.
PMID: 39535341